⌕
First Tracks Biotherapeutics · TRAX · Nasdaq
Tenet — · insufficient data
Compare
$46.56−1.15%At close
$46.56−0.54 (−1.15%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

First Tracks Biotherapeutics (TRAX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 3, 2026 · 16:15 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…

● GlobeNewsWireNov 3, 2026 · 16:15 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…

● GlobeNewsWireOct 15, 2026 · 08:00 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Announces $200 Million Private Placement

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…

● Seeking AlphaOct 14, 2026 · 08:15 ET
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements. TRAX's ANB033 demonstrat…

● Defense WorldOct 13, 2026 · 05:03 ET
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics (NASDAQ: TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-relate…

● BenzingaOct 12, 2026 · 09:55 ET
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Monday.…

● Globe News WireOct 11, 2026 · 16:00 ET
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…

● Defense WorldSep 7, 2026 · 04:41 ET
Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock

First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) Director J. Anthony Ware sold 39,265 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $44.…

● GlobeNewsWireAug 26, 2026 · 16:15 ETCOMPANY'S OWN WORDS
First Tracks Biotherapeutics Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmun…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.